

Pharmacists' Role in Managing Adverse Events in Non-Small Cell Lung Cancer Therapy: Optimizing Outcomes and Enhancing Patient Care



Autori: JASSER HADDAD, ELENI Vladimir

Conducător științific: SCUTARI Corina, dr. șt. farm., conferențiar universitar

BUECTVETS

Catedra de farmacologie și farmacie clinică, Universitatea de Stat de Medicină și Farmacie "Nicolae Testemițanu"

INTRODUCTION

non-small cell lung cancer INSCL required complexe treatments often associated with adverse effects Pharmacists contribute essentially to their management and to improving treatment results.























THE PURPOSE OF THE WORK

This study examines the impact of pharmacist interventions in NSCLC patient education, reducing adverse effects and increasing treatment success.





MATERIAL AND METHODS

The study reviewed research and clinical data on the role of pharmacists in the management of adverse effects and education of NSCLC patients, using sources from PubMed and ClinicalTrials.gov, published in the past five years

REZULTATE

Pharmacists' interventions provided significant benefits for NSCLC patients, reducing adverse effects such as nausea and fatigue. Pharmacist counseling decreased severe toxicities and increased adherence to oral treatments by 20-30%

Medication management:

- drug selection
- dosing and administration
- chemotherapy clinical review
- adverse effects management

Patient education, counselling and support:

- medication information
- lifestyle recommendations
- emotional support
- resource coordination

Collaboration with the healthcare team:

communication with oncologists and other

 monitoring and adjusting therapy

Supportive care:

- pain management
- symptom management

Adherence and compliance:

- medication adherence solutions
- follow-up monitoring

Clinical trials and research:

- information on going clinical trials
- clinical trials involvement
- access to new therapies

Conclusion

Education and management of adverse effects by pharmacists is essential for NSCLC patients, helping to increase adherence and improve treatment outcomes

KEY WORDS

non-small cell lung cancer", pharmacist-led interventions, patient education, management of adverse events